公募基金方面，本期较上一期持股增加的公募基金共计1个，即医疗器械ETF，持股增加占比达0.12%。 本期较上一季未再披露的公募基金共计138个，主要包括招商中证全指医疗器械ETF、建信中证全指医 疗保健设备与服务ETF、医服ETF、汇添富中证全指医疗器械ETF、南方中证全指医疗保健设备与服务 ETF等。 2025年10月31日，健尔康(603205.SH)发布2025年第三季报。截至2025年10月30日，共有4个机构投资者 披露持有健尔康A股股份，合计持股量达1315.51万股，占健尔康总股本的8.43%。其中，机构投资者包 括常州和聚实业投资合伙企业(有限合伙)、常州顺赢实业投资合伙企业(有限合伙)、常州清源知创创业 投资合伙企业(有限合伙)、招商银行股份有限公司-永赢中证全指医疗器械交易型开放式指数证券投资基 金，机构投资者合计持股比例达8.43%。相较于上一季度，机构持股比例合计下跌了0.12个百分点。 ...

Group 1 - The core viewpoint is that the healthcare equipment and services sector is experiencing positive momentum due to recent government initiatives aimed at supporting the high-quality development of innovative drugs and medical devices [1][2] - The CSI All Share Healthcare Equipment and Services Index (H30178) saw a significant increase, with notable stock performances including Diligent Medical (up 20.03%), Hotgen Biotech (up 9.14%), and others [1] - The National Medical Insurance Administration has initiated the 11th batch of drug procurement, focusing on optimizing procurement rules to ensure clinical stability, quality assurance, and prevent price collusion [1] Group 2 - CITIC Securities anticipates that for categories already included in national or provincial procurement, there may be price increases upon renewal, while categories not yet included may see moderate price reductions or no procurement at all [2] - The trend of optimizing procurement processes is expected to enhance market sentiment, leading to a valuation recovery for companies within the sector as they approach performance turning points in the second half of the year [2] - The CCB CSI All Share Healthcare Equipment and Services ETF (159891) closely tracks the CSI All Share Healthcare Equipment and Services Index, reflecting the overall performance of listed companies in the healthcare theme [2]

Core Viewpoint - The article emphasizes the rapid growth and significance of the Sci-Tech Innovation Board (科创板) in China's economic transformation, highlighting its role as a breeding ground for new productive forces and a witness to the fast development of high-tech sectors in China [2][4]. Group 1: Growth of Sci-Tech Innovation Board - Since its inception, the number of listed companies on the Sci-Tech Innovation Board has increased more than sevenfold, reaching 585 companies, while the total market capitalization has grown over eightfold to approximately 8309.175 billion yuan as of March 11, 2025 [2]. - The board is seen as a crucial force in the development of new productive forces, aligning with China's economic transformation [4]. Group 2: Industry Distribution and Characteristics - The Sci-Tech Innovation Board includes a diverse range of industries, with a significant focus on "hard technology," covering 17 primary industries such as electronics, biomedicine, and computer technology [16][18]. - The distribution of companies is balanced, with 44.5% in electronics, 15.2% in biomedicine, and 9.7% in computing, indicating a strong presence in emerging sectors [18]. Group 3: Investment Products and Strategies - The article introduces various investment products targeting the Sci-Tech Innovation Board, including the comprehensive ETF and Smart Beta indices, which aim to capture overall investment opportunities and enhance alpha returns through quality and valuation metrics [10][22][26]. - The Sci-Tech 200 Index focuses on smaller-cap stocks, with 82% of its sample stocks having a market capitalization below 10 billion yuan, indicating growth potential in smaller companies [27][28]. Group 4: Performance Metrics - The performance of the selected indices since 2020 shows significant volatility, with the Smart Beta index achieving a return of 78.76% in 2020, followed by varying returns in subsequent years [25]. - The article highlights the importance of focusing on companies with strong innovation capabilities and consistent R&D investment to ensure stable performance [23].

Core Points - The Shanghai Composite Index opened lower and fluctuated, while the CSI All Index for Healthcare Equipment and Services decreased by 0.16%, closing at 14,029.54 points with a trading volume of 15.519 billion yuan [1] - Over the past month, the CSI All Index for Healthcare Equipment and Services has increased by 0.23%, and over the past three months, it has risen by 2.65%, with a year-to-date increase of 2.65% [1] - The index reflects the overall performance of listed companies in the healthcare sector, selected from the CSI All Index, with a base date of December 31, 2004, set at 1,000.0 points [1] Index Composition - The top ten weighted companies in the CSI All Index for Healthcare Equipment and Services are: Mindray Medical (9.28%), Aier Eye Hospital (8.07%), United Imaging (6.7%), Aimeike (3.56%), Huatai Medical (3.16%), New Industry (3.09%), Yuyue Medical (2.83%), Meinian Onehealth (2.33%), Jiuan Medical (2.16%), and Shandong Pharmaceutical Glass (2.05%) [1] - The market share of the index's holdings is 61.07% from the Shenzhen Stock Exchange and 38.93% from the Shanghai Stock Exchange [1] - The index's holdings are entirely composed of the pharmaceutical and healthcare sector, with a 100.00% allocation [1] Index Adjustment and Fund Tracking - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the sample changes, typically remaining fixed until the next scheduled adjustment, with provisions for temporary adjustments in special circumstances [2] - Public funds tracking the healthcare index include various funds from Southern Fund, Tianhong Fund, and others, specifically designed to follow the CSI All Index for Healthcare Equipment and Services [2]